Abstract:Background: The chromodomain helicase DNA-binding protein 2 (CHD2) gene, is an ATPase and part of the CHD family of chromatin remodelers. Mutations in the CHD2 gene are inherited in an autosomal-dominant manner and can lead to intellectual disability, epilepsy, and autism. We investigated the clinical characteristics of CHD2-related conditions and their possible pathogenesis. Methods: We collected and analysed the clinical data of patients that were identified as having CHD2 mutations. Genetic testing was performed using targeted sequencing or whole-exome sequencing. We analysed the expression of CHD2 and repressor element 1-silencing transcription factor (REST) in blood samples using quantitative PCR and the conservation of the mutations. The CHD2 mutations we identified were compared with the known mutations reported in the CHD2-related literature. Results: Eight patients with CHD2 gene mutations were analysed. Six mutations were identified; four were unreported previously (c.670C>T; c.4012A>C; c.2416dup; c.1727-1728insAT), and two were known mutations: c.5035C>T (two cases) and c.4173dup (two cases). Among these mutations, seven were de novo mutations, and one could not be determined because the parents refused genetic testing. The clinical manifestations included mild or severe intellectual disability, epilepsy, and behavioural abnormalities. Quantitative PCR showed that the CHD2 gene expression levels among the patients, parents, and the controls were not significantly different. The levels of REST gene expression in the patients were significantly higher than those of the controls; thus, mutation of the CHD2 gene led to an increase in the expression level of the REST gene. The mutations reported were all located in conserved positions in different species. Among the various medications administered for treatment, valproate showed the best results for the treatment of epilepsy caused by CHD2 gene mutation. Conclusion: Mutation in CHD2 did not lead to a significant decrease in its expression level, indicating that the clinical phenotype was unrelated to its expression level, and the mutant protein may retain some function. Most of the mutations relatively stable. In addition, the clinical manifestations from the same mutation in the CHD2 gene were different among the known cases; this may be related to the regulation of REST or other regulatory factors.

Low‐grade parental gonosomal mosaicism in CHD2 siblings with Smith–Magenis‐like syndrome

Low-level germline mosaicism of a novel <i>SMARCA2</i> missense variant: Expanding the phenotypic spectrum and mode of genetic transmission

Living Birth Following Preimplantation Genetic Testing for Monogenic Disorders to Prevent Low-Level Germline Mosaicism Related Nicolaides–Baraitser Syndrome

Parental Mosaicism Detection and Preimplantation Genetic Testing in Families with Multiple Transmissions of De Novo Mutations.

Double gonosomal mosaicism as an unusual hereditary mechanism in familial GRIN2A -related disorder

Identification of of a <i>PAX2</i> mutation from maternal mosaicism causes recurrent renal disorder in siblings

46, XY gonadal dysgenesis: new SRY point mutation in two siblings with paternal germ line mosaicism

Paternal Low-Level Mosaicism-Caused SATB2-Associated Syndrome

Paternal Gonadal Mosaicism of NIPBL Mutation in a Father of Siblings with Cornelia De Lange Syndrome.

Genomic Mosaicism in Paternal Sperm and Multiple Parental Tissues in a Dravet Syndrome Cohort

CHD2 haploinsufficiency is associated with developmental delay, intellectual disability, epilepsy and neurobehavioural problems

Two Genetic Mechanisms in Two Siblings with Intellectual Disability, Autism Spectrum Disorder, and Psychosis

Lessons from a 30 year follow-up of monozygotic twins with discordant phenotype due to a ring 13 chromosomal mosaicism in one of them

Genotypes and Phenotypes of MEF2C Haploinsufficiency Syndrome: New Cases and Novel Point Mutations

Trisomy 22 Mosaicism from Prenatal to Postnatal Findings: A Case Series and Systematic Review of the Literature

Clinical Study of 8 Cases of CHD2 Gene Mutation-Related Neurological Diseases and Their Mechanisms

De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies

Somatic mosaicism detected by genome-wide sequencing in 500 parent-child trios with suspected genetic disease: clinical and genetic counseling implications

Genetic architecture of self-limited delayed puberty and congenital hypogonadotropic hypogonadism

Clinically-relevant postzygotic mosaicism in parents and children with developmental disorders in trio exome sequencing data

Genetic and phenotypic differences between sexes in congenital hypogonadotropic hypogonadism (CHH): Large cohort analysis from a single tertiary centre